U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2002
144
Substance Class Protein
Created
by admin
on Sat Dec 16 00:21:51 GMT 2023
Edited
by admin
on Sat Dec 16 00:21:51 GMT 2023
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
FYS6T7F842
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
ADALIMUMAB
EMA EPAR   HSDB   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
ADALIMUMAB, LICENSE HOLDER UNSPECIFIED
Preferred Name English
ADALIMUMAB [MI]
Common Name English
ADALIMUMAB [EMA EPAR]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN TUMOR NECROSIS FACTOR) (HUMAN MONOCLONAL D2E7 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL D2E7 LIGHT CHAIN, DIMER
Common Name English
ADALIMUMAB [USAN]
Common Name English
ADALIMUMAB (GENETICAL RECOMBINATION) [JAN]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN TUMOR NECROSIS FACTOR) (HUMAN MONOCLONAL D2E7 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL D2E7 LIGHT CHAIN, DIMER
Common Name English
LU-200134
Code English
ADALIMUMAB [HSDB]
Common Name English
ADALIMUMAB [JAN]
Common Name English
ADALIMUMAB [PURPLE BOOK CDER]
Common Name English
ADALIMUMAB [VANDF]
Common Name English
Adalimumab [WHO-DD]
Common Name English
LU200134
Code English
D2E7
Code English
ADALIMUMAB (GENETICAL RECOMBINATION)
JAN  
Common Name English
ADALIMUMAB [MART.]
Common Name English
adalimumab [INN]
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548542
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
NCI_THESAURUS C20401
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
NDF-RT N0000175610
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
EMA ASSESSMENT REPORTS TRUDEXA (WITHDRAWN: ARTHRITIS, RHEUMATOID)
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
EMA ASSESSMENT REPORTS HUMIRA (AUTHORIZED: ARTHRITIS, RHEUMATOID)
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
EMA ASSESSMENT REPORTS TRUDEXA (WITHDRAWN: CROHN DISEASE)
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
NDF-RT N0000175451
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
EMA ASSESSMENT REPORTS HUMIRA (AUTHORIZED: COLITIS, ULCERATIVE)
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
FDA ORPHAN DRUG 230306
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
FDA ORPHAN DRUG 340911
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
EMA ASSESSMENT REPORTS TRUDEXA (WITHDRAWN: SPONDYLITIS, ANKYLOSING)
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
FDA ORPHAN DRUG 318510
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
WHO-ATC L04AB04
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
FDA ORPHAN DRUG 200905
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
EMA ASSESSMENT REPORTS HUMIRA (AUTHORIZED: ARTHRITIS, JUVENILE RHEUMATOID)
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
EMA ASSESSMENT REPORTS HUMIRA (AUTHORIZED: ARTHRITIS, PSORIATIC)
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
FDA ORPHAN DRUG 436714
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
WHO-VATC QL04AB04
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
EMA ASSESSMENT REPORTS HUMIRA (AUTHORIZED: SPONDYLITIS, ANKYLOSING)
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
FDA ORPHAN DRUG 446414
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
EMA ASSESSMENT REPORTS TRUDEXA (WITHDRAWN: ARTHRITIS, PSORIATIC)
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
EMA ASSESSMENT REPORTS HUMIRA (AUTHORIZED: CROHN DISEASE)
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
Code System Code Type Description
MERCK INDEX
m1406
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY Merck Index
RXCUI
327361
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY RxNorm
RXCUI
2103477
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
ALTERNATIVE
DRUG BANK
DB00051
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY
EVMPD
SUB20016
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY
DAILYMED
FYS6T7F842
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201580
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY
NCI_THESAURUS
C65216
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY
IUPHAR
4860
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY
RXCUI
2103479
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
ALTERNATIVE
WIKIPEDIA
ADALIMUMAB
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY
SMS_ID
100000089523
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY
FDA UNII
FYS6T7F842
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY
CAS
331731-18-1
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY
INN
7860
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY
DRUG CENTRAL
4904
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY
USAN
NN-74
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY
MESH
C453439
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY
LACTMED
Adalimumab
Created by admin on Sat Dec 16 00:21:52 GMT 2023 , Edited by admin on Sat Dec 16 00:21:52 GMT 2023
PRIMARY
From To
1_22 1_96
1_148 1_204
1_224 3_214
1_230 2_230
1_233 2_233
1_265 1_325
1_371 1_429
2_22 2_96
2_148 2_204
2_224 4_214
2_265 2_325
2_371 2_429
3_23 3_88
3_134 3_194
4_23 4_88
4_134 4_194
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_301
N 2_301
Related Record Type Details
ZRC-3197
SUB_CONCEPT->SUBSTANCE
Adalimumab Fosimdesonide
CONJUGATE -> PARENT
ADALIMUMAB-FKJP
SUB_CONCEPT->SUBSTANCE
TUMOR NECROSIS FACTOR-.ALPHA. HUMAN (PLASMA DERIVED, SOLUBLE FORM)
TARGET -> INHIBITOR
ADALIMUMAB-ADBM
SUB_CONCEPT->SUBSTANCE
ADALIMUMAB-ATTO
SUB_CONCEPT->SUBSTANCE
ADALIMUMAB-BWWD
BIOSIMILAR -> PARENT
ONS-3010
SUB_CONCEPT->SUBSTANCE
BCD-057
SUB_CONCEPT->SUBSTANCE
M-923
SUB_CONCEPT->SUBSTANCE
AVT-02
PARENT -> BIOSIMILAR
ADALIMUMAB-AATY
SUB_CONCEPT->SUBSTANCE
ADALIMUMAB-AFZB
SUB_CONCEPT->SUBSTANCE
ADALIMUMAB-AFZB
BIOSIMILAR -> PARENT
Adalimumab-aqvh
BIOSIMILAR -> PARENT
ADALIMUMAB-BWWD
SUB_CONCEPT->SUBSTANCE
Adalimumab-aqvh
SUB_CONCEPT->SUBSTANCE
LBAL
SUB_CONCEPT->SUBSTANCE
ZRC-3197
SUB_CONCEPT->SUBSTANCE
ADALIMUMAB-ATTO
BIOSIMILAR -> PARENT
ZRC-3197
BIOSIMILAR -> PARENT
AVT-02
SUB_CONCEPT->SUBSTANCE
ADALIMUMAB-AATY
BIOSIMILAR -> PARENT
ADALIMUMAB-ADAZ
SUB_CONCEPT->SUBSTANCE
ADALIMUMAB (HUMIRA)
SUB_CONCEPT->SUBSTANCE
ADALIMUMAB-FKJP
BIOSIMILAR -> PARENT
Adalimumab-AACF
SUB_CONCEPT->SUBSTANCE
ADALIMUMAB-ADBM
BIOSIMILAR -> PARENT
ADALIMUMAB-ADAZ
BIOSIMILAR -> PARENT
Related Record Type Details
ADALIMUMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:SEQUENCE CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966